Net Income (Loss) Attributable to Parent in USD of ARROWHEAD PHARMACEUTICALS, INC. from Q2 2010 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Arrowhead Pharmaceuticals, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and change rate from Q2 2010 to Q3 2025.
  • Arrowhead Pharmaceuticals, Inc. Net Income (Loss) Attributable to Parent for the quarter ending 30 Sep 2025 was -$23.8M, a 86.1% increase year-over-year.
  • Arrowhead Pharmaceuticals, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending 30 Sep 2025 was -$1.63M, a 99.7% increase year-over-year.
  • Arrowhead Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2025 was -$1.63M, a 99.7% increase from 2024.
  • Arrowhead Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2024 was -$599M, a 192% decline from 2023.
  • Arrowhead Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$205M, a 16.6% decline from 2022.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Change (%)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Change (%)

ARROWHEAD PHARMACEUTICALS, INC. Quarterly Net Income (Loss) Attributable to Parent (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 -$1.63M -$23.8M +$147M +86.1% 01 Jul 2025 30 Sep 2025 10-K 25 Nov 2025
Q2 2025 -$148M -$175M -$4.45M -2.6% 01 Apr 2025 30 Jun 2025 10-Q 07 Aug 2025
Q1 2025 -$144M $370M +$496M 01 Jan 2025 31 Mar 2025 10-Q 12 May 2025
Q4 2024 -$640M -$173M -$40.2M -30.3% 01 Oct 2024 31 Dec 2024 10-Q 10 Feb 2025
Q3 2024 -$599M -$171M -$60.9M -55.5% 01 Jul 2024 30 Sep 2024 10-K 25 Nov 2025
Q2 2024 -$539M -$171M -$67.8M -65.9% 01 Apr 2024 30 Jun 2024 10-Q 07 Aug 2025
Q1 2024 -$471M -$125M -$174M -357% 01 Jan 2024 31 Mar 2024 10-Q 12 May 2025
Q4 2023 -$297M -$133M -$91.5M -222% 01 Oct 2023 31 Dec 2023 10-Q 10 Feb 2025
Q3 2023 -$205M -$110M -$24.2M -28.3% 01 Jul 2023 30 Sep 2023 10-K 25 Nov 2025
Q2 2023 -$181M -$103M -$30.9M -42.9% 01 Apr 2023 30 Jun 2023 10-Q 08 Aug 2024
Q1 2023 -$150M $48.7M +$4.31M +9.71% 01 Jan 2023 31 Mar 2023 10-Q 09 May 2024
Q4 2022 -$155M -$41.3M +$21.5M +34.3% 01 Oct 2022 31 Dec 2022 10-Q 06 Feb 2024
Q3 2022 -$176M -$85.5M -$22.1M -34.9% 01 Jul 2022 30 Sep 2022 10-K 26 Nov 2024
Q2 2022 -$154M -$72M -$42.1M -141% 01 Apr 2022 30 Jun 2022 10-Q 07 Aug 2023
Q1 2022 -$112M $44.4M +$71.2M 01 Jan 2022 31 Mar 2022 10-Q 07 Aug 2023
Q4 2021 -$183M -$62.9M -$42.1M -203% 01 Oct 2021 31 Dec 2021 10-Q 07 Aug 2023
Q3 2021 -$141M -$63.4M -$14.9M -30.8% 01 Jul 2021 30 Sep 2021 10-K 29 Nov 2023
Q2 2021 -$126M -$29.9M -$16.3M -120% 01 Apr 2021 30 Jun 2021 10-Q 04 Aug 2022
Q1 2021 -$110M -$26.8M -$6.98M -35.2% 01 Jan 2021 31 Mar 2021 10-Q 10 May 2022
Q4 2020 -$103M -$20.7M -$18.1M -676% 01 Oct 2020 31 Dec 2020 10-Q 02 Feb 2022
Q3 2020 -$84.6M -$48.4M -$60.1M -514% 01 Jul 2020 30 Sep 2020 10-K 28 Nov 2022
Q2 2020 -$24.4M -$13.6M -$33.9M -167% 01 Apr 2020 30 Jun 2020 10-Q 05 Aug 2021
Q1 2020 $9.53M -$19.8M -$43.7M -183% 01 Jan 2020 31 Mar 2020 10-Q 04 May 2021
Q4 2019 $53.3M -$2.67M -$14.7M -122% 01 Oct 2019 31 Dec 2019 10-Q 04 Feb 2021
Q3 2019 $68M $11.7M +$22.5M 01 Jul 2019 30 Sep 2019 10-K 22 Nov 2021
Q2 2019 $45.5M $20.3M +$35.9M 01 Apr 2019 30 Jun 2019 10-Q 05 Aug 2020
Q1 2019 $9.57M $23.9M +$38.8M 01 Jan 2019 31 Mar 2019 10-Q 07 May 2020
Q4 2018 -$29.2M $12M +$25.2M 01 Oct 2018 31 Dec 2018 10-Q 05 Feb 2020
Q3 2018 -$54.5M -$10.8M -$29.4K -0.27% 01 Jul 2018 30 Sep 2018 10-K 23 Nov 2020
Q2 2018 -$54.4M -$15.6M -$10.1M -183% 01 Apr 2018 30 Jun 2018 10-Q 05 Aug 2019
Q1 2018 -$44.3M -$14.9M -$8.84M -146% 01 Jan 2018 31 Mar 2018 10-Q 08 May 2019
Q4 2017 -$35.5M -$13.2M -$1.11M -9.21% 01 Oct 2017 31 Dec 2017 10-Q 07 Feb 2019
Q3 2017 -$34.4M -$10.7M +$11.5M +51.7% 01 Jul 2017 30 Sep 2017 10-K 12 Dec 2017
Q2 2017 -$45.9M -$5.52M +$13.9M +71.6% 01 Apr 2017 30 Jun 2017 10-K 12 Dec 2017
Q1 2017 -$59.8M -$6.04M +$14.8M +71% 01 Jan 2017 31 Mar 2017 10-K 12 Dec 2017
Q4 2016 -$74.5M -$12.1M +$7.18M +37.3% 01 Oct 2016 31 Dec 2016 10-K 12 Dec 2017
Q3 2016 -$81.7M -$22.2M +$2.52M +10.2% 01 Jul 2016 30 Sep 2016 10-K 12 Dec 2017
Q2 2016 -$84.2M -$19.4M -$3.48M -21.9% 01 Apr 2016 30 Jun 2016 10-K 12 Dec 2017
Q1 2016 -$80.8M -$20.8M +$7.87M +27.4% 01 Jan 2016 31 Mar 2016 10-K 12 Dec 2017
Q4 2015 -$88.6M -$19.3M +$3.31M +14.7% 01 Oct 2015 31 Dec 2015 10-K 12 Dec 2017
Q3 2015 -$91.9M -$24.7M -$2.31M -10.3% 01 Jul 2015 30 Sep 2015 10-K 14 Dec 2016
Q2 2015 -$89.6M -$15.9M -$4.31M -37.1% 01 Apr 2015 30 Jun 2015 10-K 14 Dec 2016
Q1 2015 -$85.3M -$28.7M -$14.7M -106% 01 Jan 2015 31 Mar 2015 10-K 14 Dec 2016
Q4 2014 -$70.6M -$22.6M -$11.9M -112% 01 Oct 2014 31 Dec 2014 10-K 14 Dec 2016
Q3 2014 -$58.6M -$22.4M -$8.74M -63.8% 01 Jul 2014 30 Sep 2014 10-K 14 Dec 2015
Q2 2014 -$49.9M -$11.6M -$5.55M -91.3% 01 Apr 2014 30 Jun 2014 10-K 14 Dec 2015
Q1 2014 -$44.3M -$13.9M -$7.18M -106% 01 Jan 2014 31 Mar 2014 10-K 14 Dec 2015
Q4 2013 -$37.2M -$10.6M -$6.01M -130% 01 Oct 2013 31 Dec 2013 10-K 14 Dec 2015
Q3 2013 -$31.1M -$13.7M -$8.38M -158% 01 Jul 2013 30 Sep 2013 10-K 25 Nov 2014
Q2 2013 -$22.8M -$6.08M +$1.91M +23.9% 01 Apr 2013 30 Jun 2013 10-K 25 Nov 2014
Q1 2013 -$24.7M -$6.76M -$1.42M -26.7% 01 Jan 2013 31 Mar 2013 10-K 25 Nov 2014
Q4 2012 -$23.3M -$4.61M -$2.13M -85.6% 01 Oct 2012 31 Dec 2012 10-K 25 Nov 2014
Q3 2012 -$21.1M -$5.31M -$2.54M -91.4% 01 Jul 2012 30 Sep 2012 10-K 25 Nov 2014
Q2 2012 -$18.6M -$7.99M -$6.17M -339% 01 Apr 2012 30 Jun 2012 10-Q 07 Aug 2013
Q1 2012 -$12.4M -$5.34M -$8.24M -284% 01 Jan 2012 31 Mar 2012 10-Q 09 May 2013
Q4 2011 -$4.18M -$2.49M -$1.05M -72.9% 01 Oct 2011 31 Dec 2011 10-Q 13 Feb 2013
Q3 2011 -$3.13M -$2.78M 01 Jul 2011 30 Sep 2011 10-K 28 Dec 2012
Q2 2011 -$1.82M -$1.45M -390% 01 Apr 2011 30 Jun 2011 10-Q 13 Aug 2012
Q1 2011 $2.91M 01 Jan 2011 31 Mar 2011 10-Q 08 May 2012
Q4 2010 -$1.44M 01 Oct 2010 31 Dec 2010 10-Q 09 Feb 2012
Q2 2010 -$371K 01 Apr 2010 30 Jun 2010 10-Q 08 Aug 2011

ARROWHEAD PHARMACEUTICALS, INC. Annual Net Income (Loss) Attributable to Parent (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2025 -$1.63M +$598M +99.7% 01 Oct 2024 30 Sep 2025 10-K 25 Nov 2025
2024 -$599M -$394M -192% 01 Oct 2023 30 Sep 2024 10-K 25 Nov 2025
2023 -$205M -$29.2M -16.6% 01 Oct 2022 30 Sep 2023 10-K 25 Nov 2025
2022 -$176M -$35.2M -25% 01 Oct 2021 30 Sep 2022 10-K 26 Nov 2024
2021 -$141M -$56.3M -66.6% 01 Oct 2020 30 Sep 2021 10-K 29 Nov 2023
2020 -$84.6M -$153M -224% 01 Oct 2019 30 Sep 2020 10-K 28 Nov 2022
2019 $68M +$122M 01 Oct 2018 30 Sep 2019 10-K 22 Nov 2021
2018 -$54.5M -$20.1M -58.4% 01 Oct 2017 30 Sep 2018 10-K 23 Nov 2020
2017 -$34.4M +$47.3M +57.9% 01 Oct 2016 30 Sep 2017 10-K 25 Nov 2019
2016 -$81.7M +$10.2M +11.1% 01 Oct 2015 30 Sep 2016 10-K 14 Dec 2016
2015 -$91.9M -$33.3M -56.8% 01 Oct 2014 30 Sep 2015 10-K 14 Dec 2016
2014 -$58.6M -$27.5M -88.3% 01 Oct 2013 30 Sep 2014 10-K 14 Dec 2016
2013 -$31.1M -$10M -47.4% 01 Oct 2012 30 Sep 2013 10-K 14 Dec 2015
2012 -$21.1M -$18M -575% 01 Oct 2011 30 Sep 2012 10-K 25 Nov 2014
2011 -$3.13M +$2.65M +45.8% 01 Oct 2010 30 Sep 2011 10-K 28 Dec 2012
2010 -$5.77M 01 Oct 2009 30 Sep 2010 10-K 20 Dec 2011
* An asterisk sign (*) next to the value indicates that the value is likely invalid.